Genesis Therapeutics

Genesis Therapeutics (Genesis Molecular AI) is an AI-focused biotechnology company building GEMS (Genesis Exploration of Molecular Space), a generative and predictive AI operating system for small-molecule drug discovery. GEMS combines structure-based deep learning, language and diffusion models, and physics-based simulation (molecular dynamics and quantum chemistry) to generate and optimize molecules for complex targets, accelerating hit identification through lead optimization and candidate selection. In 2025 the company introduced Pearl, a next-generation foundation model for drug discovery. Headquartered in Burlingame, California with a laboratory in San Diego, Genesis has raised over $300M and partners with Eli Lilly, Gilead, Genentech, and Incyte while advancing its own therapeutic pipeline. It is not a public API provider: GEMS is a proprietary internal platform with no published developer portal, documentation, or API.

Genesis Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Artificial Intelligence, Machine-Learning, Drug Discovery, and Biotechnology.

🌐 Visit website 📡 Source on GitHub

3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyArtificial IntelligenceMachine-LearningDrug DiscoveryBiotechnologyLife SciencesPharmaceuticalsMolecular AI

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 3.3/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/genesis-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: genesis-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/genesis-therapeutics.png
name: Genesis Therapeutics
description: 'Genesis Therapeutics (Genesis Molecular AI) is an AI-focused biotechnology company building GEMS (Genesis Exploration
  of Molecular Space), a generative and predictive AI operating system for small-molecule drug discovery. GEMS combines structure-based
  deep learning, language and diffusion models, and physics-based simulation (molecular dynamics and quantum chemistry) to
  generate and optimize molecules for complex targets, accelerating hit identification through lead optimization and candidate
  selection. In 2025 the company introduced Pearl, a next-generation foundation model for drug discovery. Headquartered in
  Burlingame, California with a laboratory in San Diego, Genesis has raised over $300M and partners with Eli Lilly, Gilead,
  Genentech, and Incyte while advancing its own therapeutic pipeline. It is not a public API provider: GEMS is a proprietary
  internal platform with no published developer portal, documentation, or API.'
url: https://raw.githubusercontent.com/api-evangelist/genesis-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- menlo-ventures
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Artificial Intelligence
- Machine-Learning
- Drug Discovery
- Biotechnology
- Life Sciences
- Pharmaceuticals
- Molecular AI
tags_raw:
- Company
- Artificial Intelligence
- Machine Learning
- Drug Discovery
- Biotechnology
- Life Sciences
- Pharmaceuticals
- Molecular AI
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/genesis-therapeutics-domain-security.yml
- type: Website
  url: https://genesis.ml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence

Genesis Therapeutics

Kin Score

Security Posture 1

Genesis Therapeutics Domain Security

Resources

Access & Security 1

Company 1

Source (apis.yml)